Results
Title

Is Hyperuricemia Overlooked when Treating Pediatric Tuberculosis Patients with Pyrazinamide?

Authors

Şişmanlar, Tuğba; Aslan, Ayşe T.; Budakoğlu, Irem

Abstract

The treatment of tuberculosis (TB) requires long-term multiple drug use. Hyperuricemia is frequently reported in adults, but there are few data for the pediatric population. This study aimed to review drug-related side effects in pediatric patients that received treatment for TB. Patients with active TB undergoing treatment were followed for drug-related side effects. During the 7 year period, 23 patients with a mean age of 7.9 ± 4.66 years were treated. Drug-related side effects were observed in 14 patients. Hyperuricemia occurred in 12 of the 14 patients, vs. hepatotoxicity in 2. In all, eight of the patients with hyperuricemia had ≥2 episodes during pyrazinamide (PZA) therapy. Based on these findings, we devised an algorithm that could be used for the management of hyperuricemia in patients receiving PZA because of TB, and recommend that hyperuricemia be closely monitored during PZA therapy.

Subjects

DRUG therapy for tuberculosis; ALLOPURINOL; ANTITUBERCULAR agents; DRUG administration; DRUG side effects; HYPERURICEMIA; MYCOBACTERIUM tuberculosis; URIC acid; TREATMENT effectiveness; RETROSPECTIVE studies; PYRAZINAMIDE; THERAPEUTICS

Publication

Journal of Tropical Pediatrics, 2015, Vol 61, Issue 5, p351

ISSN

0142-6338

Publication type

Academic Journal

DOI

10.1093/tropej/fmv042